When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering.

Messerli, Franz H; Rimoldi, Stefano; Bangalore, Sripal; Bavishi, Chirag; Laurent, Stephane (2016). When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. Journal of the American College of Cardiology, 68(7), pp. 754-762. Elsevier 10.1016/j.jacc.2016.03.610

[img] Text
1-s2.0-S073510971633488X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (928kB)

An elevated resting heart rate has been unequivocally linked to adverse cardiovascular events. Conversely, a physiologically low heart rate may confer longevity benefits. Moreover, pharmacological heart rate lowering reduces cardiovascular outcomes in patients with heart failure, with the magnitude of the reduction associated with survival benefit. In contrast, pharmacological heart rate lowering paradoxically increases cardiovascular events in hypertension, possibly because it elicits a ventricular-vascular mismatch, leading to increased central systolic blood pressure (BP). By the same hemodynamic mechanism, pharmacological heart rate lowering also engenders an increase in central (aortic) BP in coronary heart disease and, as a consequence, fails to decrease myocardial oxygen consumption. Whether in heart failure, hypertension, or coronary heart disease, or even athletes, heart rate lowering consistently increases central systolic pressure. The increase in central systolic BP is prone to abolish the potential benefits of heart rate lowering interventions, possibly accounting for failure to reduce outcomes in patients with hypertension and coronary artery disease.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Kardiologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Kardiologie

UniBE Contributor:

Rimoldi, Stefano

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0735-1097

Publisher:

Elsevier

Language:

English

Submitter:

Stefano Rimoldi

Date Deposited:

16 May 2017 10:57

Last Modified:

05 Dec 2022 15:02

Publisher DOI:

10.1016/j.jacc.2016.03.610

PubMed ID:

27515336

Uncontrolled Keywords:

beta-blockers; blood pressure; coronary artery disease; heart failure; hypertension; ivabradine

BORIS DOI:

10.7892/boris.95031

URI:

https://boris.unibe.ch/id/eprint/95031

Actions (login required)

Edit item Edit item
Provide Feedback